Success developed and packaged

At the core of our efforts and investment in this complex, futuristic field is the customer, for whom we develop cost-effective biopharmaceuticals to treat life-threatening ailments.

Wockhardt’s pioneering efforts in biotechnology have led to the launch of three successful products in the Indian market - Biovac-B (hepatitis B vaccine), Wepox (erythropoietin), and Wosulin (recombinant insulin).

Biovac-B is a WHO GMP certified hepatitis B vaccine. Wepox, Wockhardt’s recombinant erythropoietin, is for the treatment of anaemia caused by cancer and chronic renal failure. Wepox has been created by mammalian cell culture and meets European Pharmacopoeia standards. Wosulin is the first r-DNA insulin developed and manufactured outside the US and Europe. It has been manufactured through the latest yeast based expression system. A recent addition to the Company’s product basket is Wosulin Pen & Cartridge, an automatic insulin delivery device - for the convenience of diabetic patients.

The company has also made a breakthrough with Glargine (a novel long-acting insulin). Growth stimulating factors (GSF) are also in the development pipeline.